Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback